[Regional therapy @entity0 liver XXXX ].

@entity1 @entity632 @entity0 @entity66 @entity5 @entity1138 @entity3 @entity1487
The prognosis of @entity1 with metastatic @entity0 in particular with an involvement of the liver has to be regarded as rather unfavourable. Up today no convincing therapy for @entity1 with @entity0 and liver @entity3 could be found. From 1982 to 1991 42 @entity1 with suspicion on liver @entity3 of a primary @entity0 were laparotomized. At that time 20 @entity1 already had an extrahepatic formation of @entity3 . In contrast to the preexaminations an histologically benign liver @entity5 was intraoperatively verified in 6 @entity1 . In the other 36 @entity1 the operation was finished in 9 cases as explorative laparotomy (group A) because of extensive intra- and @entity66 . In 19 cases an arterial catheter system with subcutaneous port was implanted (group B). Partial liver resection combined with intraarterial catheter implantation was performed in 8 @entity1 (group C). Postoperatively 27 @entity1 monthly received a regional combined chemotherapy (groups B+C); a modified FAM scheme ( @entity1487 : 1000 mg/12 h/d/2 d, @entity632 : 20 mg/12 h/d/3 d, @entity1138 : 10 mg/2 h/d/1 d) was used. Response could be documented in 12 out of 17 evaluable @entity1 (70.6%). A median overall postoperative survival time of 14.5 months for all @entity1 in case of a proved liver @entity3 was calculated. A prolongation could not be realized, neither in @entity1 with partial liver resection with regional therapy (group C) nor in @entity1 with an intraarterial chemotherapy (group B). Only in exceptional cases a successful regional chemotherapy could influence the course favourable.(ABSTRACT TRUNCATED AT 250 WORDS)
